TP53 and cancer: These approaches could include: (i) determining the wtAAV persistence in CSCs and the clinical consequences of its potential replication on CSCs and cancer cells, (ii) exploiting the ITR toxicity in CSCs, (iii) examining the potential interaction between the p53 transcriptional binding sites on AAV ITR sequences and CSC stemness, and (iv) the potential inhibitory effects of wtAAV on CSCs.